In The Lancet today, investigators from the Japanese Gynecologic Oncology Group (JGOG) report results from their phase 3 trial,1 showing benefit from a dose-dense (once weekly) schedule of paclitaxel compared with standard dosing of once every 3 weeks in women with newly diagnosed epithelial ovarian, fallopian, or primary peritoneal carcinoma. During the past 12 years, development of international phase 3 trials has been facilitated through the Gynecologic Cancer InterGroup (GCIG).2 Collaborative...